ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Acrivon Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.69+0.05 (+3.05%)
Close on Oct 19, 2026
- Market cap
- $70.71M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Acrivon Therapeutics has not reported a dividend
No dividend per share appears in Acrivon Therapeutics's annual filings since fiscal 2020.